CA2990565A1 - Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain - Google Patents

Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain Download PDF

Info

Publication number
CA2990565A1
CA2990565A1 CA2990565A CA2990565A CA2990565A1 CA 2990565 A1 CA2990565 A1 CA 2990565A1 CA 2990565 A CA2990565 A CA 2990565A CA 2990565 A CA2990565 A CA 2990565A CA 2990565 A1 CA2990565 A1 CA 2990565A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2990565A
Other languages
English (en)
Inventor
Hiroyuki Sonoda
Kenichi Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JCR Pharmaceuticals Co Ltd
Original Assignee
JCR Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JCR Pharmaceuticals Co Ltd filed Critical JCR Pharmaceuticals Co Ltd
Publication of CA2990565A1 publication Critical patent/CA2990565A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Abstract

L'invention fournit une protéine hybride contenant un facteur neurotrophique dérivé du cerveau (BDNF). Cette protéine hybride consiste en une protéine hybride du BDNF et d'un anticorps anti-récepteur de transferrine humaine dans une plage spécifique. Le BDNF administré dans le sang peut passer au travers de la barrière hématoencéphalique.
CA2990565A 2015-06-24 2016-06-24 Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain Pending CA2990565A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015144380 2015-06-24
JP2015-144380 2015-06-24
PCT/JP2016/068739 WO2016208696A1 (fr) 2015-06-24 2016-06-24 Protéine hybride contenant un bdnf

Publications (1)

Publication Number Publication Date
CA2990565A1 true CA2990565A1 (fr) 2016-12-29

Family

ID=57585589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2990565A Pending CA2990565A1 (fr) 2015-06-24 2016-06-24 Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain

Country Status (9)

Country Link
US (2) US11130815B2 (fr)
EP (1) EP3315515A4 (fr)
JP (1) JP6914193B2 (fr)
KR (1) KR20180020279A (fr)
CN (1) CN107849150B (fr)
AU (1) AU2016283344B2 (fr)
CA (1) CA2990565A1 (fr)
HK (2) HK1245298A1 (fr)
WO (1) WO2016208696A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY187033A (en) 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
CA2990565A1 (fr) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain
BR112019009316A2 (pt) * 2016-12-26 2019-08-06 Japan Chem Res anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
KR102573622B1 (ko) * 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
CN110114078B (zh) * 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) * 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
PT3583120T (pt) 2017-02-17 2022-12-15 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
CN116964213A (zh) 2021-03-10 2023-10-27 住友制药株式会社 融合蛋白的制造方法
CA3238914A1 (fr) 2021-11-19 2023-05-25 Jcr Pharmaceuticals Co., Ltd. Peptide ayant une affinite pour le recepteur de la transferrine humaine

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
CA2123307A1 (fr) 1991-11-26 1993-06-10 Phillip M. Friden Methode de preparation de conjugues d'anticorps contre le recepteur de la transferrine avec un produit neuropharmaceutique ou un agent de diagnostic
JPH06228199A (ja) 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
EP0599303A3 (fr) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Conjugués peptidiques
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
EP1197755A1 (fr) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification de sites de liaison de protéines
EP2189473A3 (fr) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
AU2003262886A1 (en) 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
SI1979001T1 (sl) 2005-12-13 2012-08-31 Medimmune Ltd Vezni proteini specifiäśno za inzulinu podobne rastne faktorje in njih uporaba
EP1979001B1 (fr) 2005-12-13 2012-04-11 Medimmune Limited Proteines de liaison specifiques des facteurs de croissance analogues a l'insuline et utilisations de celles-ci
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN101245107B (zh) 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
CA2607771A1 (fr) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela
US20100077498A1 (en) 2008-09-11 2010-03-25 Pardridge William M Compositions and methods for blood-brain barrier delivery in the mouse
WO2010037395A2 (fr) 2008-10-01 2010-04-08 Dako Denmark A/S Multimères de mhc dans des vaccins et la surveillance immunitaire contre le cancer
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
ES2569514T3 (es) 2009-06-17 2016-05-11 Biomarin Pharmaceutical Inc. Formulaciones para enzimas lisosómicas
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
JP2012034668A (ja) 2010-08-12 2012-02-23 Tohoku Univ ヒト型化抗ｅｇｆｒ抗体リジン置換可変領域断片及びその利用
JP2012062312A (ja) 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
TW201247706A (en) 2011-03-08 2012-12-01 Baylor Res Inst Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
WO2012143379A1 (fr) * 2011-04-20 2012-10-26 Roche Glycart Ag Procédé et hybrides destinés au passage dépendant du ph de la barrière hémato-encéphalique
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
TW201400132A (zh) * 2012-05-21 2014-01-01 Genentech Inc 改善血腦屏障運送之安全性之方法
PL2935331T3 (pl) 2012-12-24 2018-07-31 Abbvie Inc. Białka wiążące receptor prolaktyny i ich zastosowania
US9708406B2 (en) 2013-05-20 2017-07-18 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3003368A4 (fr) 2013-05-24 2017-05-03 Biogen MA Inc. Anticorps anti-gpiib/iiia ou leurs utilisations
TW201536811A (zh) 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
ES2745566T3 (es) 2013-06-11 2020-03-02 Portage Pharmaceuticals Ltd Estructura, fabricación y usos de péptidos que pueden penetrar en las células derivados de seres humanos conjugados con péptidos de carga biológicamente activos específicos
WO2015009961A1 (fr) 2013-07-19 2015-01-22 Armagen Technologies, Inc. Compositions et procédés associés à des structures qui traversent la barrière hémato-encéphalique
MA38797A1 (fr) 2013-08-02 2018-06-29 Hoffmann La Roche Protéine de fusion thérapeutique
EP3088518A4 (fr) 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Nouvel anticorps anti-récepteur de transferrine qui traverse la barrière hémato-encéphalique
KR102381685B1 (ko) 2014-01-06 2022-04-01 에프. 호프만-라 로슈 아게 1가 혈액 뇌 장벽 셔틀 모듈
CA2874083C (fr) 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
CA2990565A1 (fr) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Proteine de fusion contenant un bdnf et un anticorps du recepteur de la transferrine anti-humain
MY187033A (en) 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
SG10202007520WA (en) 2016-03-02 2020-09-29 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
WO2018038243A1 (fr) 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 Procédé de production d'une protéine de fusion d'anticorps
KR102573622B1 (ko) 2016-12-26 2023-08-31 제이씨알 파마 가부시키가이샤 Bdnf를 포함하는 융합 단백질
BR112019009316A2 (pt) 2016-12-26 2019-08-06 Japan Chem Res anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
CN110114078B (zh) 2016-12-28 2024-01-30 Jcr制药股份有限公司 冷冻干燥制剂
EP3679945A4 (fr) 2017-09-07 2021-06-16 JCR Pharmaceuticals Co., Ltd. Composition pharmaceutique aqueuse

Also Published As

Publication number Publication date
EP3315515A1 (fr) 2018-05-02
HK1247933A1 (zh) 2018-10-05
KR20180020279A (ko) 2018-02-27
JP6914193B2 (ja) 2021-08-04
US20180179291A1 (en) 2018-06-28
CN107849150B (zh) 2021-12-14
AU2016283344B2 (en) 2022-08-04
AU2016283344A1 (en) 2018-02-01
US20210309754A1 (en) 2021-10-07
JPWO2016208696A1 (ja) 2018-04-12
CN107849150A (zh) 2018-03-27
WO2016208696A1 (fr) 2016-12-29
US11958905B2 (en) 2024-04-16
HK1245298A1 (zh) 2018-08-24
US11130815B2 (en) 2021-09-28
EP3315515A4 (fr) 2019-06-05

Similar Documents

Publication Publication Date Title
US11958905B2 (en) Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody
JP7427046B2 (ja) Ｂｄｎｆを含む融合蛋白質
CN107683289B (zh) IL13Rα2结合剂和其在癌症治疗中的用途
CN107835820B (zh) 识别癌症特异性IL13Rα2的CAR T细胞
RU2769352C2 (ru) Антитела и полипептиды, направленные против cd127
AU2018370279B2 (en) Antibodies to a-synuclein and uses thereof
CN110972463B (zh) 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
TW201106963A (en) Antigen-binding proteins
HUE033960T2 (en) Monoclonal Antibodies to ANGPTL3
US11780916B2 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
CN110945029A (zh) 用于治疗的药剂、用途和方法
FR3075200A1 (fr) Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc
CA2871417C (fr) Anticorps anti-cd69 humain, et application medicale de celui-ci
EP3808847A1 (fr) Anticorps apj, protéine de fusion de celui-ci avec elabela, et compositions pharmaceutiques et utilisation associées
US20240228637A9 (en) Chemokine receptor 8 (ccr8) antibodies
US20240132604A1 (en) Chemokine receptor 8 (ccr8) antibodies
KR102507337B1 (ko) 항 메소텔린 scFv를 포함하는 키메릭 항원 수용체 및 이의 용도
JP2023504974A (ja) 抗ｔｉｒｃ７抗原結合タンパク質

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608

EEER Examination request

Effective date: 20210608